Somatic mutations are present in all members of the AKT family in endometrial carcinoma by Dutt, A et al.
Letter to the Editor
Somatic mutations are present in all members of the AKT family in
endometrial carcinoma
A Dutt
1,2, HB Salvesen
3,4, H Greulich
1,2,5, WR Sellers
6, R Beroukhim*,1,2,5,7,8 and M Meyerson*,1,2,8,9,10
1Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA;
2Cancer Program, The Broad Institute of
MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA;
3Department of Clinical Medicine, The University of Bergen, Bergen 5020, Norway;
4Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen N-5021, Norway;
5Department of Medicine, Brigham and Women’s
Hospital, 75 Francis Street, Boston, MA 02115, USA;
6Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA 02139,
USA;
7Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA;
8Department of Medicine, Harvard Medical School,
Boston, MA 02115, USA;
9Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA;
10Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
British Journal of Cancer (2009) 101, 1218–1219. doi:10.1038/sj.bjc.6605301 www.bjcancer.com
Published online 8 September 2009
& 2009 Cancer Research UK
                           
Sir,
The activating E17K mutations recently discovered in the
pleckstrin homology domain of AKT1 in about 2% of endometrial
cancer patients (Shoji et al, 2009) suggest a new mechanism for PI3
kinase pathway activation in these patients, as previously
described in breast, colorectal and ovarian cancers (Carpten
et al, 2007). Additional mechanisms of PI3 kinase pathway
activation in endometrial cancer include the somatic mutation of
PTEN and PIK3CA (Kong et al, 1997; Oda et al, 2005),
amplification and overexpression of PIK3CA (Miyake et al, 2008;
Salvesen et al, 2009), and decreased expression of PTEN
(Kanamori et al, 2001; Kappes et al, 2001).
We found an additional four mutations in AKT family members
(Table 1). Two of these (mutations in the catalytic domain of AKT2
(D399N) and the regulatory domain of AKT3 (E438D)) were
previously reported in a sequencing screen of 123 genes in 41
primary endometrial cancers (Dutt et al, 2008). Manual reinspec-
tion of these data in light of the report on activating AKT1
mutations in endometrial cancer (Shoji et al, 2009) revealed an
additional mutation, AKT1 E17K, identical to the one reported by
Shoji et al (2009), and a novel mutation in the catalytic domain of
AKT2 (R368C) in two additional samples. We validated these
mutations as somatic by mass spectrometric genotyping of the
tumour and matched normal DNA, after an independent PCR
amplification. We also found a novel candidate mutation in the
pleckstrin homology domain of AKT2 (D32H), which we could not
validate because of insufficient DNA. All these mutations occurred
in cancers of the endometrioid subtype that had no signs of
metastasis either at primary treatment or during follow-up. Taken
together, we find that 5 out of 41 endometrial cancers have
mutations in AKT family members for a 12% rate.
Confirmation that these novel mutations activate the PI3 kinase
pathway awaits their functional characterisation. Notably, all the
AKT family member mutations found in our data occur at residues
conserved across multiple species (see Supplementary Figure 1).
However, three of these five mutations were identified in samples
harbouring mutations of PTEN, one of which also had amplification
of and a mutation in PIK3CA (Table 1); the AKT1 E17K mutation is
not associated with either PTEN or PIK3CA genomic alteration. It is
therefore possible that these AKT family mutations have different
functional effects from mutations of PTEN and PIK3CA. Given the
importance of the PI3 kinase pathway in endometrial cancer
oncogenesis (Salvesen et al, 2009), and the emerging therapeutic
options for PI3 kinase inhibition (Garcia-Echeverria and Sellers,
2008), the functional effects of all these AKT family mutations should
be investigated in appropriate model systems of endometrial cancer.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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Table 1 AKT family mutations found in endometrial cancer
Gene
Sample
ID Mutation Domain
PIK3CA
amplification
a
Other
mutations
AKT1 436T E17K Pleckstrin
homology
No KRAS (G13D)
AKT2 288T D399N Regulatory
C-terminal
No PTEN (D24Y,
F341Y, R130Q)
AKT2 426T R368C Catalytic
kinase
No CTNNB1 (S37Y)
AKT2 141T D32H
b Pleckstrin
homology
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AKT3 192T E438D Regulatory
C-terminal
Yes PTEN (R130Q),
PIK3CA (R88Q)
aDetermined by segmentation analysis of normalised signal intensities from 100K
single-nucleotide polymorphism arrays as previously reported (Salvesen et al, 2009).
bCandidate mutation not validated by mass spectrometric genotyping.
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